Emerging drugs for respiratory syncytial virus infection

Author： Olszewska Wieslawa Openshaw Peter

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.14, Iss.2, 2009-06, pp. : 207-217

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Respiratory Syncytial Virus Infection in Elderly Adults

By Falsey Ann R. Walsh Edward E.

Drugs & Aging, Vol. 22, Iss. 7, 2005-01 ,pp. : 577-587

Adis International

Access to resources Recommend Favorite

Respiratory Syncytial Virus Infection in Adult Populations

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 12, Iss. 2, 2012-04 ,pp. : 98-102

Bentham Science Publishers

Access to resources Recommend Favorite

Immune-mediated disease pathogenesis in respiratory syncytial virus infection

By Graham B.S. Johnson T.R. Peebles R.S.

Immunopharmacology, Vol. 48, Iss. 3, 2000-07 ,pp. : 237-247

Elsevier

Access to resources Recommend Favorite

Palivizumab: A Review of its Use as Prophylaxis for Serious Respiratory Syncytial Virus Infection

By Fenton Caroline Scott Lesley J. Plosker Greg L.

Pediatric Drugs, Vol. 6, Iss. 3, 2004-01 ,pp. : 177-197

Adis International

Access to resources Recommend Favorite

Recent developments in the treatment and prevention of respiratory syncytial virus infection

By Krilov Leonard R

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 3, 2002-03 ,pp. : 441-449

Informa Healthcare

Access to resources Recommend Favorite